Nabriva Therapeutics Statistics Share Statistics Nabriva Therapeutics has 3.2M
shares outstanding. The number of shares has increased by -93.8%
in one year.
Shares Outstanding 3.2M Shares Change (YoY) -93.8% Shares Change (QoQ) -95.15% Owned by Institutions (%) n/a Shares Floating 3.01M Failed to Deliver (FTD) Shares 28 FTD / Avg. Volume 0.2%
Short Selling Information The latest short interest is 33.67K, so 0% of the outstanding
shares have been sold short.
Short Interest 33.67K Short % of Shares Out n/a Short % of Float 1.13% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.09 and the forward
PE ratio is null.
Nabriva Therapeutics's PEG ratio is
0.
PE Ratio -0.09 Forward PE n/a PS Ratio 0.14 Forward PS n/a PB Ratio 1.54 P/FCF Ratio -0.14 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Nabriva Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.13,
with a Debt / Equity ratio of 1.59.
Current Ratio 1.13 Quick Ratio 0.78 Debt / Equity 1.59 Debt / EBITDA -0.1 Debt / FCF -0.14 Interest Coverage -79.5
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $914.56K Profits Per Employee $-1.47M Employee Count 39 Asset Turnover 1.12 Inventory Turnover 2.95
Taxes Income Tax 1.57M Effective Tax Rate -2.82%
Stock Price Statistics The stock price has increased by 125.4% in the
last 52 weeks. The beta is 1.55, so Nabriva Therapeutics's
price volatility has been higher than the market average.
Beta 1.55 52-Week Price Change 125.4% 50-Day Moving Average 1.28 200-Day Moving Average 1.65 Relative Strength Index (RSI) 34.11 Average Volume (20 Days) 13,843
Income Statement In the last 12 months, Nabriva Therapeutics had revenue of 35.67M
and earned -57.19M
in profits. Earnings per share was -21.32.
Revenue 35.67M Gross Profit 7.09M Operating Income -55.49M Net Income -57.19M EBITDA -54.7M EBIT -50.6M Earnings Per Share (EPS) -21.32
Full Income Statement Balance Sheet The company has 12.41M in cash and 5.22M in
debt, giving a net cash position of 7.19M.
Cash & Cash Equivalents 12.41M Total Debt 5.22M Net Cash 7.19M Retained Earnings -652.86M Total Assets 24.34M Working Capital -4.3M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -36.71M
and capital expenditures -211K, giving a free cash flow of -36.92M.
Operating Cash Flow -36.71M Capital Expenditures -211K Free Cash Flow -36.92M FCF Per Share -13.77
Full Cash Flow Statement Margins Gross margin is 19.87%, with operating and profit margins of -155.57% and -160.33%.
Gross Margin 19.87% Operating Margin -155.57% Pretax Margin -155.93% Profit Margin -160.33% EBITDA Margin -153.36% EBIT Margin -155.57% FCF Margin -103.52%
Dividends & Yields NBRV does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for NBRV.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 16, 2022. It was a
backward
split with a ratio of 1:25.
Last Split Date Sep 16, 2022 Split Type backward Split Ratio 1:25
Scores Altman Z-Score -43.78 Piotroski F-Score 3
